GlassScriptPhysician profile
William W Moore
NPI 1407089907
$6,218.43
in general payments reported to CMS, 2019-2025
33 companies · $983 in 2025
The $983 reported for 2025 was more than what 85% of Nurse Practitioner providers received nationally (typical 2025 total: $174).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $1,433 · 2022: $1,638 · 2023: $1,168 · 2024: $996 · 2025: $983.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,147.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,147.40 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Medtronic, INC. | $1,617.93 | 2021-2025 | Minimed 780g, Inceptiv, Inpen Smart Insulin Delivery System |
| Novo Nordisk INC | $868.95 | 2021-2025 | Ozempic, Rybelsus, Wegovy |
| Lilly USA, LLC | $624.45 | 2021-2025 | Mounjaro, Zepbound, Jardiance |
| Astrazeneca Pharmaceuticals LP | $392.99 | 2021-2024 | Fasenra, Farxiga, Airsupra |
| Corcept Therapeutics | $365.52 | 2021-2025 | Korlym |
| Abbott Laboratories | $329.40 | 2022-2025 | Freestyle Libre 2, Freestyle Libre 3 |
| Abbvie INC. | $307.50 | 2021-2024 | |
| Pfizer INC. | $185.14 | 2021-2024 | |
| Janssen Pharmaceuticals, INC | $179.81 | 2022-2024 | Spravato |
| Boehringer Ingelheim Pharmaceuticals, INC. | $159.83 | 2021-2024 | Jardiance |
| Sanofi-Aventis U.S. LLC | $144.08 | 2022 | |
| Takeda Pharmaceuticals U.S.A., INC. | $130.35 | 2021-2024 | Glassia |
| Silk Road Medical, INC. | $120.01 | 2024 | Enroute Transcarotid Neuroprotection System, Enroute Enflate Transcarotid Rx Balloon Dilatation Catheter, Enroute Transcarotid Stent |
| Amgen INC. | $112.76 | 2021-2025 | Evenity |
| Exact Sciences Corporation | $92.26 | 2024-2025 | Cologuard Collection Kit |
Show all 33 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Xeris Pharmaceuticals, INC. | $69.15 | 2025 | Gvoke Hypopen |
| Idorsia Pharmaceuticals US INC | $53.61 | 2022-2023 | Quviviq |
| Glaxosmithkline, LLC. | $50.50 | 2021 | |
| Novartis Pharmaceuticals Corporation | $46.58 | 2022-2023 | |
| Biohaven Pharmaceutical Holding Company LTD. | $42.05 | 2022 | |
| Horizon Therapeutics Plc | $38.76 | 2022 | |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $36.53 | 2024-2025 | Lifevest |
| Dexcom, INC. | $34.43 | 2022-2023 | Dexcom G6 Transmitter |
| Insulet Corporation | $34.17 | 2025 | Omnipod |
| Kowa Pharmaceuticals America, INC. | $33.83 | 2021-2022 | |
| Sumitomo Pharma America, INC. | $32.80 | 2024 | Gemtesa |
| Arbor Pharmaceuticals, INC. | $28.85 | 2021 | |
| Esperion Therapeutics, INC. | $18.86 | 2022 | |
| Mylan Specialty L.P. | $18.72 | 2022 | |
| Biohaven Pharmaceuticals, INC. | $13.35 | 2021 | |
| Grt US Holding, INC. | $12.54 | 2021 | |
| Astellas Pharma US INC | $12.08 | 2021 | |
| Tandem Diabetes Care, INC. | $10.64 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw William Moore listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.